A start-up development company accused controversial biotechnology outfit iQ Group Global of pilfering plans to commercialise a saliva-testing device.
The dispute in the NSW Supreme Court, revealed on Monday by The Australian Financial Review, alleges development business Disrupt Group Holdings passed on commercially sensitive information to iQ chief executive George Syrmalis about the device, theoretically to help diabetics.
Loading...
Jonathan Shapiro writes about banking and finance, specialising in hedge funds, corporate debt, private equity and investment banking. He is based in Sydney. Connect with Jonathan on Twitter. Email Jonathan at jonathan.shapiro@afr.com
Liam Walsh writes on investigations and companies with The Australian Financial Review. He has won multiple media awards, worked in Japan and is now based in Brisbane. Email Liam at liam.walsh@afr.com.au
